Nothing Special   »   [go: up one dir, main page]

BRPI0921701B8 - Cefarosporina tendo um grupo catecol, seu uso e composição farmacêutica que a compreende - Google Patents

Cefarosporina tendo um grupo catecol, seu uso e composição farmacêutica que a compreende

Info

Publication number
BRPI0921701B8
BRPI0921701B8 BRPI0921701A BRPI0921701A BRPI0921701B8 BR PI0921701 B8 BRPI0921701 B8 BR PI0921701B8 BR PI0921701 A BRPI0921701 A BR PI0921701A BR PI0921701 A BRPI0921701 A BR PI0921701A BR PI0921701 B8 BRPI0921701 B8 BR PI0921701B8
Authority
BR
Brazil
Prior art keywords
compound
single bond
pharmaceutical composition
catechol group
optionally substituted
Prior art date
Application number
BRPI0921701A
Other languages
English (en)
Inventor
Hideki Sugimoto
Kenji Yamawaki
Shinya Hisakawa
Toshiaki Aoki
Yasuhiro Nishitani
Yusuke Takeoka
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42128829&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0921701(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of BRPI0921701A2 publication Critical patent/BRPI0921701A2/pt
Publication of BRPI0921701B1 publication Critical patent/BRPI0921701B1/pt
Publication of BRPI0921701B8 publication Critical patent/BRPI0921701B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
    • C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D505/00—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D505/10—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D505/12—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7
    • C07D505/14—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7 with hetero atoms directly attached in position 7
    • C07D505/16—Nitrogen atoms
    • C07D505/18—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof
    • C07D505/20—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D505/24—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen further substituted by doubly-bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/06—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 containing at least one condensed beta-lactam ring system, provided for by groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00, e.g. a penem or a cepham system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

composto cefalosporinas tendo um grupo catecol, uso do mesmo e composição farmacêutica compreendendo o dito composto. a presente invenção refere-se a compostos cefem que têm um amplo espectro antimicrobiano e têm potente atividade antimicrobiana contra bactérias gram-negativas produtoras de beta-lactamase, como segue: um composto da fórmula: fórmula 1 (i) em que, x é n, ch ou c-ci; t é s ou similares; a e g são alquileno inferior ou similar; b é uma ligação simples ou similar; d é uma ligação simples, nr7-, co-, co-nr7-, nr7-co-, -nr7 -co-nr7-, ou similares; e é alquileno inferior opcionalmente substituído; f é uma ligação simples ou fenileno opcionalmente substituído; r3, r4, r5 e r6 são, cada um independentemente, hidrogênio, halogênio, nitrila, ou similares; ou um éster, um composto protegido no amino do anel na cadeia lateral 7, um sal farmaceuticamente aceitável, ou um solvato do mesmo.
BRPI0921701A 2008-10-31 2009-10-27 Cefarosporina tendo um grupo catecol, seu uso e composição farmacêutica que a compreende BRPI0921701B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008280828 2008-10-31
JP2008-280828 2008-10-31
PCT/JP2009/068400 WO2010050468A1 (ja) 2008-10-31 2009-10-27 カテコール基を有するセファロスポリン類

Publications (3)

Publication Number Publication Date
BRPI0921701A2 BRPI0921701A2 (pt) 2020-08-11
BRPI0921701B1 BRPI0921701B1 (pt) 2022-05-03
BRPI0921701B8 true BRPI0921701B8 (pt) 2022-06-07

Family

ID=42128829

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921701A BRPI0921701B8 (pt) 2008-10-31 2009-10-27 Cefarosporina tendo um grupo catecol, seu uso e composição farmacêutica que a compreende

Country Status (38)

Country Link
US (1) US9238657B2 (pt)
EP (2) EP2960244B1 (pt)
JP (2) JP5498393B2 (pt)
KR (1) KR101655961B1 (pt)
CN (1) CN102203100B (pt)
AU (1) AU2009310959B2 (pt)
BR (1) BRPI0921701B8 (pt)
CA (1) CA2736953C (pt)
CL (1) CL2011000939A1 (pt)
CO (1) CO6331443A2 (pt)
CR (1) CR20110144A (pt)
CY (2) CY1118536T1 (pt)
DK (1) DK2960244T3 (pt)
EA (1) EA019520B1 (pt)
ES (2) ES2564836T3 (pt)
FI (1) FIC20200039I1 (pt)
FR (1) FR20C1050I2 (pt)
HR (1) HRP20161408T1 (pt)
HU (2) HUE031802T2 (pt)
IL (1) IL211720A (pt)
LT (2) LT2960244T (pt)
MA (1) MA32731B1 (pt)
ME (1) ME02666B (pt)
MX (1) MX2011004636A (pt)
MY (1) MY155655A (pt)
NL (1) NL301067I2 (pt)
NO (1) NO2020035I1 (pt)
NZ (1) NZ591728A (pt)
PE (1) PE20120010A1 (pt)
PL (1) PL2960244T3 (pt)
PT (1) PT2960244T (pt)
RS (1) RS55365B1 (pt)
SI (1) SI2960244T1 (pt)
SM (1) SMT201600397B (pt)
TW (1) TWI535727B (pt)
UA (1) UA105190C2 (pt)
WO (1) WO2010050468A1 (pt)
ZA (1) ZA201102024B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2702257C (en) 2007-10-09 2016-07-12 Sopharmia, Inc. Broad spectrum beta-lactamase inhibitors
AU2009310959B2 (en) * 2008-10-31 2015-05-07 Shionogi & Co., Ltd. Cephalosporin having catechol group
CN102918047A (zh) * 2010-04-05 2013-02-06 盐野义制药株式会社 具有假儿茶酚基团的头孢烯类化合物
CN102918048A (zh) * 2010-04-05 2013-02-06 盐野义制药株式会社 具有儿茶酚基团的头孢烯类化合物
JP5852562B2 (ja) * 2010-04-28 2016-02-03 塩野義製薬株式会社 新規なセフェム誘導体
EP2966061B1 (en) 2011-03-04 2017-05-03 Life Technologies Corporation Compounds and methods for conjugation of biomolecules
KR101719556B1 (ko) * 2011-03-30 2017-03-24 주식회사 레고켐 바이오사이언스 신규한 세파로스포린 유도체 및 이를 함유하는 의약 조성물
US9334289B2 (en) * 2011-04-28 2016-05-10 Shionogi & Co., Ltd. Cephem compound having catechol or pseudo-catechol structure
WO2013002215A1 (ja) 2011-06-27 2013-01-03 塩野義製薬株式会社 ピリジニウム基を有するセフェム化合物
TWI547496B (zh) * 2011-10-04 2016-09-01 葛蘭素集團公司 抗菌化合物
WO2013051597A1 (ja) 2011-10-04 2013-04-11 塩野義製薬株式会社 カテコール基を有するセフェム誘導体
UY35103A (es) 2012-10-29 2014-05-30 Glaxo Group Ltd Compuestos de cefem 2-sustituidos
US9527866B2 (en) 2012-10-29 2016-12-27 Shionogi & Co., Ltd. Processes for production of intermediates for 2-alkyl cephem compounds
WO2014104148A1 (ja) * 2012-12-26 2014-07-03 塩野義製薬株式会社 セフェム化合物
US10376496B2 (en) 2013-09-09 2019-08-13 Merck, Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
BR112016020333B1 (pt) 2014-03-24 2022-08-09 Novartis Ag Compostos orgânicos de monobactam, seus usos, composições e combinações farmacêuticas
JP6377570B2 (ja) * 2014-04-28 2018-08-22 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ ２−置換セフェム化合物を含有する医薬組成物
WO2015191907A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN106661052B (zh) * 2014-09-04 2021-05-11 盐野义制药株式会社 头孢菌素衍生物的中间体及其制造方法
PL3190115T3 (pl) * 2014-09-04 2021-12-27 Shionogi & Co., Ltd. Sól pochodnej cefalosporyny, jej krystaliczna postać stała i sposób jej wytwarzania
JP6218204B2 (ja) * 2014-09-04 2017-10-25 塩野義製薬株式会社 カテコール基を有するセファロスポリン類を含有する製剤
EP3307725A1 (en) 2015-06-11 2018-04-18 Basilea Pharmaceutica International AG Efflux-pump inhibitors and therapeutic uses thereof
RU2754180C2 (ru) 2015-09-23 2021-08-30 Новартис Аг Соли и твердые формы монобактамного антибиотика
WO2017096472A1 (en) 2015-12-10 2017-06-15 Naeja-Rgm Pharmaceuticals Inc. Cephem compounds, their production and use
JP6918819B2 (ja) 2016-03-08 2021-08-11 ノバルティス アーゲー オルトミクソウイルス感染の処置に有用な三環式化合物
EP3471724A1 (en) * 2016-06-17 2019-04-24 Wockhardt Limited Antibacterial compositions
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
WO2018218154A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP3634471A4 (en) * 2017-06-09 2021-02-24 FOB Synthesis, Inc. CARBAPENEM COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS
EP3661933B1 (en) 2017-08-02 2022-03-23 Novartis AG Process for preparing 1-(((z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3s,4r)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3- yl)amino)ethylidene)amino)oxy)cyclopropane carboxylic acid
CA3092544A1 (en) 2018-02-28 2019-09-06 Novartis Ag 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza
WO2020184399A1 (ja) * 2019-03-08 2020-09-17 塩野義製薬株式会社 抗菌用医薬組成物
KR20220061163A (ko) 2019-09-06 2022-05-12 나브리바 테라퓨틱스 게엠베하 사이드로포어 세팔로스포린 접합체 및 이의 용도
BR112022014321A2 (pt) * 2020-01-22 2022-09-13 Shanghai Senhui Medicine Co Ltd Composto antibacteriano de cefalosporina e aplicação farmacêutica do mesmo
TW202220663A (zh) 2020-07-28 2022-06-01 日商鹽野義製藥股份有限公司 含有具有鄰苯二酚基之頭孢菌素類的凍結乾燥製劑及其製造方法
TW202241913A (zh) 2021-01-12 2022-11-01 大陸商上海森輝醫藥有限公司 一種頭孢類抗菌化合物及其製備方法
CN113698365A (zh) * 2021-08-30 2021-11-26 成都大学 一种头孢地尔侧链的制备方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47168A (en) 1974-05-09 1979-07-25 Toyama Chemical Co Ltd Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same
JPS57118588A (en) 1981-11-26 1982-07-23 Toyama Chem Co Ltd Novel cephalosporin
DE3207840A1 (de) 1982-03-04 1983-09-15 Hoechst Ag, 6230 Frankfurt "cephalosporinderivate und verfahren zu ihrer herstellung"
GR79784B (pt) 1983-01-21 1984-10-31 Beecham Group Plc
NO165842C (no) 1984-04-23 1991-04-17 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive cefem-forbindelser.
EP0168177A3 (en) 1984-06-28 1987-04-01 Pfizer Limited Cephalosporin antibiotics
EP0203271B1 (en) 1985-03-01 1993-05-26 Takeda Chemical Industries, Ltd. Antibacterial compounds, their production and use
JPH068300B2 (ja) * 1985-08-02 1994-02-02 萬有製薬株式会社 新規セフアロスポリン誘導体
EP0211656A3 (en) 1985-08-10 1988-03-09 Beecham Group Plc Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them
DE3687200T2 (de) * 1985-09-03 1993-05-27 Otsuka Kagaku Kk Cephalosporinderivate.
JPH07107069B2 (ja) * 1985-09-03 1995-11-15 大塚化学株式会社 セフアロスポリン化合物の新規誘導体、その製造法及び該誘導体を含有する医薬組成物
JPS62158291A (ja) * 1986-01-07 1987-07-14 Sagami Chem Res Center セフアロスポリン誘導体
EP0241901B1 (en) 1986-04-14 1994-08-24 Banyu Pharmaceutical Co., Ltd. Cephalosporin derivatives, processes for their preparation and antibacterial agents
US5084453A (en) 1986-04-14 1992-01-28 Banyu Pharmaceutical Co., Ltd. 1-carboxy-1-vinyloxyimino aminothiazole cephalosporin derivatives
IE61679B1 (en) * 1987-08-10 1994-11-16 Fujisawa Pharmaceutical Co Water-soluble antibiotic composition and water-soluble salts of new cephem compounds
GB8719875D0 (en) 1987-08-22 1987-09-30 Beecham Group Plc Compounds
JPH0228185A (ja) * 1988-04-14 1990-01-30 Tanabe Seiyaku Co Ltd セファロスポリン化合物及びその合成中間体
US5149803A (en) * 1988-05-10 1992-09-22 Imperial Chemical Industries Plc Intermediates for cephalosporin compounds
GB8811055D0 (en) 1988-05-10 1988-06-15 Ici Plc Antibiotic compounds
PH25965A (en) 1988-06-06 1992-01-13 Fujisawa Pharmaceutical Co New cephem compounds which have antimicrobial activities
US5244890A (en) * 1988-06-06 1993-09-14 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
GB8813945D0 (en) 1988-06-13 1988-07-20 Fujisawa Pharmaceutical Co New cephem compounds & process for preparation thereof
GB8817653D0 (en) 1988-07-25 1988-09-01 Fujisawa Pharmaceutical Co New cephem compounds & processes for preparation thereof
JPH02275886A (ja) 1988-12-29 1990-11-09 Tanabe Seiyaku Co Ltd セファロスポリン化合物及びその製法
CA2005787A1 (en) 1988-12-29 1990-06-29 Masao Wada Cephalosporin compounds
US5143910A (en) * 1989-09-07 1992-09-01 Shionogi & Co., Ltd. Piperaziniocephalosporins
GB9005246D0 (en) 1990-03-08 1990-05-02 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
US5126336A (en) * 1990-08-23 1992-06-30 Bristol-Myers Squibb Company Antibiotic c-3 catechol-substituted cephalosporin compounds, compositions and method of use thereof
US5234920A (en) 1990-08-23 1993-08-10 Bristol-Myers Squibb Company Antibiotic C-7 catechol-substituted cephalosporin compounds, compositions, and method of use thereof
US5095012A (en) 1990-08-23 1992-03-10 Bristol-Myers Squibb Company Antibiotic c-7 catechol-substituted cephalosporin compounds, compositions, and method of use thereof
US5194433A (en) * 1990-11-13 1993-03-16 Bristol-Myers Squibb Company Antibiotic c-3 catechol-substituted cephalosporin compounds, compositions and method of use thereof
GB9111406D0 (en) 1991-05-28 1991-07-17 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
GB9118672D0 (en) 1991-08-30 1991-10-16 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
EP0628562A1 (fr) 1993-06-10 1994-12-14 Roussel Uclaf Céphalosporines comportant en position 7 un radical oxymino substitué, leurs intermédiaires, leurs procédé de préparation et leur application comme médicaments
AU1694099A (en) 1997-12-26 1999-07-19 Cheil Jedang Corporation Cephem derivatives and a method for producing the compounds and an antibacterialcomposition containing the compounds
HUP0402508A2 (hu) 2001-03-27 2005-03-29 Actelion Pharmaceuticals Ltd. 1,2,3,4-Tetrahidro-izokinolin-származékok mint urotenzin II receptor antagonisták és a vegyületeket tartalmazó gyógyszerkészítmények
JP2003078440A (ja) 2001-08-30 2003-03-14 Kyocera Corp 高周波スイッチ回路
TW200305422A (en) 2002-03-18 2003-11-01 Shionogi & Co Broad spectrum cefem compounds
US6713625B2 (en) 2002-05-23 2004-03-30 Orchid Chemicals & Pharmaceuticals Ltd. Process for the preparation of cefditoren using the thioester of thiazolylacetic acid
JP4892926B2 (ja) 2005-10-25 2012-03-07 宇部興産株式会社 スルホン化芳香族ブロック共重合体の製造方法
TW200637559A (en) 2005-03-29 2006-11-01 Shionogi & Co 3-propenylcefem derivative
JP4557859B2 (ja) 2005-09-29 2010-10-06 富士通株式会社 周波数分割多重送受信装置及び送受信方法
WO2007096740A2 (en) 2006-02-20 2007-08-30 Orchid Research Laboratories Limited Novel cephalosporins
US20090012054A1 (en) 2006-03-16 2009-01-08 Astellas Pharma Inc. Cephem Compounds and Use as Antimicrobial Agents
AU2009310959B2 (en) 2008-10-31 2015-05-07 Shionogi & Co., Ltd. Cephalosporin having catechol group
CN102918047A (zh) * 2010-04-05 2013-02-06 盐野义制药株式会社 具有假儿茶酚基团的头孢烯类化合物
CN102918048A (zh) * 2010-04-05 2013-02-06 盐野义制药株式会社 具有儿茶酚基团的头孢烯类化合物
JP5852562B2 (ja) * 2010-04-28 2016-02-03 塩野義製薬株式会社 新規なセフェム誘導体

Also Published As

Publication number Publication date
EP2341053A4 (en) 2012-08-08
DK2960244T3 (en) 2016-11-28
HUS2000042I1 (hu) 2020-11-30
CR20110144A (es) 2011-09-09
US20110190254A1 (en) 2011-08-04
JP5498393B2 (ja) 2014-05-21
AU2009310959A1 (en) 2010-05-06
NL301067I1 (pt) 2020-10-13
HUE031802T2 (en) 2017-08-28
KR20110090982A (ko) 2011-08-10
ME02666B (me) 2017-06-20
ZA201102024B (en) 2014-08-27
IL211720A0 (en) 2011-06-30
CN102203100B (zh) 2014-08-27
RS55365B1 (sr) 2017-03-31
JPWO2010050468A1 (ja) 2012-03-29
EP2960244B1 (en) 2016-09-14
EP2341053B1 (en) 2016-01-13
CA2736953A1 (en) 2010-05-06
NZ591728A (en) 2012-12-21
CY2020034I1 (el) 2020-11-25
PE20120010A1 (es) 2012-02-07
SMT201600397B (it) 2017-01-10
NO2020035I1 (no) 2020-10-21
CL2011000939A1 (es) 2011-09-16
CY2020034I2 (el) 2021-05-05
MA32731B1 (fr) 2011-10-02
ES2564836T3 (es) 2016-03-29
NL301067I2 (nl) 2020-10-28
CN102203100A (zh) 2011-09-28
CO6331443A2 (es) 2011-10-20
HRP20161408T1 (hr) 2016-12-02
MY155655A (en) 2015-11-13
LTPA2020530I1 (lt) 2020-11-10
LT2960244T (lt) 2016-11-25
KR101655961B1 (ko) 2016-09-08
EA201170632A1 (ru) 2011-12-30
FIC20200039I1 (fi) 2020-10-19
UA105190C2 (ru) 2014-04-25
ES2602969T3 (es) 2017-02-23
AU2009310959B2 (en) 2015-05-07
CY1118536T1 (el) 2017-07-12
SI2960244T1 (sl) 2017-02-28
EA019520B1 (ru) 2014-04-30
CA2736953C (en) 2017-07-11
EP2960244A1 (en) 2015-12-30
PL2960244T3 (pl) 2017-03-31
TW201020259A (en) 2010-06-01
EP2341053A1 (en) 2011-07-06
MX2011004636A (es) 2011-06-20
FR20C1050I2 (fr) 2021-10-15
BRPI0921701B1 (pt) 2022-05-03
PT2960244T (pt) 2016-11-02
IL211720A (en) 2015-01-29
WO2010050468A1 (ja) 2010-05-06
FR20C1050I1 (pt) 2020-11-27
TWI535727B (zh) 2016-06-01
BRPI0921701A2 (pt) 2020-08-11
US9238657B2 (en) 2016-01-19
JP2014065732A (ja) 2014-04-17

Similar Documents

Publication Publication Date Title
BRPI0921701B8 (pt) Cefarosporina tendo um grupo catecol, seu uso e composição farmacêutica que a compreende
CL2014003181A1 (es) Compuestos derivados de benzamidas n- sustituidas o piridinamidas n-sustituidas; composicion farmaceutica que los comprende; metodo de tratamiento; y su uso para el tratamiento de enfermedades o trastornos seleccionados de dolor, depresion y enfermedades cardiovasculares, respiratorias o psiquiatricas o combinaciones de estas.
BRPI0809977A8 (pt) Uso de um composto, compostos e composição farmacêutica que o contém
EA200802058A1 (ru) Производные циклоалкиламинокислот и их фармацевтические композиции
EA200802390A1 (ru) Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их
NZ752732A (en) Oxysterols and methods of use thereof
GT200800189A (es) Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g
MY147390A (en) Substituted isoindoles as bace inhibitors and their use
BR112012033770A2 (pt) novo derivado de nicotinamida ou sal do mesmo
MY152535A (en) Novel 6-triazolopyridazinesulfanyl benzothiazole and benzimidazole derivatives, method for production thereof and application as medicaments and pharmaceutical compositions and novel use as met inhibitors
NO20083434L (no) Benzamid- og heteroarenderivater
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
GB0612423D0 (en) Therapeutic agents
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
NI201100050A (es) Derivados amida de heteroarilos su uso como activadores de glucoquinasa.
BRPI1009333B8 (pt) compostos inibidores de beta-secretase, seus usos, bem como composição farmacêutica
BR112013011580A2 (pt) derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep
AR074604A1 (es) Derivados de 5-amino-2-(1-hidroxi-etil)-tetrahidropirano.
AR074608A1 (es) Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas
TW200612936A (en) Indole derivatives
EA201170722A1 (ru) Лактамы в качестве ингибиторов бета-секретазы
TW200637817A (en) 5-aminoindole derivatives
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
BRPI0507903A (pt) derivados de quinazolina e composição farmacêutica compreendendo os mesmos

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/10/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2678 DE 03/05/2022 QUANTO AO NUMERO DO WO COD. INID (87).

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2678 DE 03/05/2022 QUANTO A DATA DE PUBLICACAO DO PCT (INID 87).